Insider Selling: MannKind (NASDAQ:MNKD) Director Sells $55,732.60 in Stock

Posted by Brian Himes on May 16th, 2026

MannKind Corporation (NASDAQ:MNKD – Get Free Report) Director Steven Binder sold 16,940 shares of the firm’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $3.29, for a total value of $55,732.60. Following the completion of the sale, the director owned 808,008 shares of the company’s stock, valued at $2,658,346.32. This represents a 2.05% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

MannKind Trading Down 4.0%

Shares of MNKD stock opened at $3.09 on Friday. The stock has a 50 day moving average of $2.74 and a two-hundred day moving average of $4.50. MannKind Corporation has a 12 month low of $2.23 and a 12 month high of $6.51. The company has a market capitalization of $954.66 million, a P/E ratio of -44.14 and a beta of 1.04.

MannKind (NASDAQ:MNKD – Get Free Report) last announced its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.03). MannKind had a negative return on equity of 11.21% and a negative net margin of 6.63%.The firm had revenue of $90.17 million during the quarter, compared to the consensus estimate of $105.38 million. During the same quarter in the prior year, the business posted $0.04 EPS. MannKind’s revenue was up 15.1% compared to the same quarter last year. Sell-side analysts predict that MannKind Corporation will post -0.04 earnings per share for the current fiscal year.

Institutional Investors Weigh In On MannKind

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its holdings in MannKind by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 17,880,873 shares of the biopharmaceutical company’s stock valued at $101,385,000 after purchasing an additional 250,290 shares in the last quarter. State Street Corp increased its holdings in MannKind by 36.2% during the 4th quarter. State Street Corp now owns 14,623,269 shares of the biopharmaceutical company’s stock valued at $82,914,000 after purchasing an additional 3,883,071 shares in the last quarter. Rubric Capital Management LP acquired a new stake in MannKind during the 3rd quarter valued at $61,297,000. UBS Group AG increased its holdings in MannKind by 146.7% during the 3rd quarter. UBS Group AG now owns 5,194,739 shares of the biopharmaceutical company’s stock valued at $27,896,000 after purchasing an additional 3,088,820 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in MannKind by 11.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 4,953,295 shares of the biopharmaceutical company’s stock valued at $12,134,000 after purchasing an additional 509,692 shares in the last quarter. 49.55% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms recently commented on MNKD. Wells Fargo & Company raised their target price on MannKind from $8.00 to $10.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. Wall Street Zen downgraded MannKind from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Weiss Ratings downgraded MannKind from a “hold (c)” rating to a “sell (d+)” rating in a research report on Monday, March 2nd. HC Wainwright raised their target price on MannKind from $8.00 to $10.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Finally, Royal Bank Of Canada raised their target price on MannKind from $3.50 to $4.75 and gave the stock a “sector perform” rating in a research report on Thursday, May 7th. Seven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, MannKind has a consensus rating of “Moderate Buy” and an average target price of $8.84.

Check Out Our Latest Research Report on MNKD

About MannKind

(Get Free Report)

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF).